Review article · 2024 · Open access
Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management
Endocrinology and Metabolism, 39(2), 206–221 · Published 16 April 2024 · DOI 10.3803/enm.2024.1940
In brief
“Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management” is a 2024 review article by Jang Won Son and Soo Kyung Lim, published in Endocrinology and Metabolism. OpenAlex counts 45 citations as of 21 November 2026, which puts it in the top 3% of works published in 2024 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Endocrinology and Metabolism.
- Citations
- 45
- Most cited in
- 2026 (28)
- Field-weighted impact
- 1.86
- References
- 115
- Authors
- 2
Abstract
Obesity is a significant risk factor for health issues like type 2 diabetes and cardiovascular disease. It often proves resistant to traditional lifestyle interventions, prompting a need for more precise therapeutic strategies. This has led to a focus on signaling pathways and neuroendocrine mechanisms to develop targeted obesity treatments. Recent developments in obesity management have been revolutionized by introducing novel glucagon-like peptide-1 (GLP-1) based drugs, such as semaglutide and tirzepatide. These drugs are part of an emerging class of nutrient-stimulated hormone-based therapeutics, acting as incretin mimetics to target G-protein-coupled receptors like GLP-1, glucose-dependent insulinotropic polypeptide (GIP), and glucagon. These receptors are vital in regulating body fat and energy balance. The development of multiagonists, including GLP-1-glucagon and GIP-GLP-1-glucagon receptor agonists, especially with the potential for glucagon receptor activation, marks a significant advancement in the field. This review covers the development and clinical efficacy of various GLP-1-based therapeutics, exploring the challenges and future directions in obesity management.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Son, J. W., & Lim, S. K. (2024). Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management. Endocrinology and Metabolism, 39(2), 206–221. https://doi.org/10.3803/enm.2024.1940
MLA 9
Son, Jang Won, and Soo Kyung Lim. “Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.” Endocrinology and Metabolism, vol. 39, no. 2, 2024, pp. 206–221. https://doi.org/10.3803/enm.2024.1940.
Chicago
Son, Jang Won and Soo Kyung Lim. 2024. “Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.” Endocrinology and Metabolism 39 (2): 206–221. https://doi.org/10.3803/enm.2024.1940.
Harvard
Son, J. W. and Lim, S. K. (2024) ‘Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management’, Endocrinology and Metabolism, 39(2), pp. 206–221. doi:10.3803/enm.2024.1940.
IEEE
J. W. Son and S. K. Lim, “Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management,” Endocrinology and Metabolism, vol. 39, no. 2, pp. 206–221, 2024, doi: 10.3803/enm.2024.1940.
BibTeX
@article{son2024glucagon,
title = {{Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management}},
author = {Son, Jang Won and Lim, Soo Kyung},
journal = {Endocrinology and Metabolism},
year = {2024},
volume = {39},
number = {2},
pages = {206--221},
doi = {10.3803/enm.2024.1940},
url = {https://doi.org/10.3803/enm.2024.1940}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 5 | |
| 2025 | 12 | |
| 2026 | 28 |
Its field-weighted citation impact is 1.86: it has been cited 1.86 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- obesity
- glucagon-like peptide-1
- GLP-1 receptor agonists
- semaglutide
- tirzepatide
- incretin mimetics
- glucose-dependent insulinotropic polypeptide
- glucagon receptor agonist
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Son, J. W., & Lim, S. K. (2024). Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management. Endocrinology and Metabolism, 39(2), 206–221. https://doi.org/10.3803/enm.2024.1940
How many times has this paper been cited?
45 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Endocrinology and Metabolism: sign in and open the PDF from this page.
Who wrote this paper?
Jang Won Son, Soo Kyung Lim.
What is the DOI of this paper?
10.3803/enm.2024.1940, permanently at https://doi.org/10.3803/enm.2024.1940. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.